Morningstar

Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells

- Cordex Biologics, an ExCellThera company, is actively seeking strategic partnerships to accelerate the commercialization of Zemcelpro® in Europe and other markets MONTREAL, August 27, 2025 ...
ascopubs.org

Extracellular (EC) Mucin5AC (MUC5AC) detection after neoadjuvant therapy (NAT) and the risk of recurrence in resected pancreatic ductal adenocarcinoma (R-PDA).

Adjuvant mFOLFIRINOX (mFFX) for resected pancreatic cancer (PC): Long term clinical and genomic outcomes. A phase I/II open-label clinical trial of CPI-613 in combination with modified FOLFIRINOX in ...
Business Wire

Enzychem Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis

ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biotechnology company, announced today that the Company has filed for Breakthrough Therapy designation ...
Yahoo Finance

BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi (Revised)

Bristol Myers Squibb BMY obtained the European Commission’s (“EC”) approval for a label expansion of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T ...
Nasdaq

BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi

Bristol Myers Squibb BMY obtained the European Commission’s (“EC”) approval for a label expansion of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T ...